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Abstract 
Background: Artificial tears have been among the first line of therapy in management of Dry Eye Syndrome 
(DES). This study was conducted to compare a local artificial tear with an imported one in reduction of DES. 
This comparison would help to evaluate the cost and benefits of each drop in the proper management of DES. 
Materials and Methods: In this double-blind randomized clinical trial study, a total 65 students meeting our 
inclusion criteria for DES entered the study. The OSDI questionnaire, TBUT, corneal and conjunctival staining 
and Schirmer test, were performed. The patients were divided into two groups by block randomization. Group 
1 received first drop and group 2 received second drop. Both groups were instructed to use the drops 4 times a 
day for 14 days. The same tests were performed by the same examiner who was blind to the treatment type 
after two weeks. Repeated measured ANOVA was used to analyze the data. 
Results: A total of 58 patients completed the study. In both groups, after the intervention, the OSDI scores 
(P<0.001), TBUT score (P=0.041), corneal (P<0.001) and conjunctival staining scores (P<0.001) showed 
improvement in compare to those before the intervention. However, the Schirmer test score did not show 
significantly difference before and after intervention. In comparing two groups the OSDI scores, the TBUT 
score, the corneal and conjunctival staining scores and the Schirmer scores did not show statistically 
significant difference. 
Conclusion: The two artificial tears equally reduced the symptoms and signs of DES in two weeks. 
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Dry eye syndrome (DES) is a multifactorial disease 
caused by a disturbance in the lacrimal function unit. 
The components of this unit are the lacrimal glands, 
ocular surface and the lids which are all connected by 
the sensory and motor nerves. This unit controls the 
tear film and responds to environmental, 
endocrinological and cortical stimuli1. This condition 
can be caused by lack of tears, excessive evaporation 
of tears, or inflammatory diseases of the eye and 
eyelid. The patients with DES usually feel discomfort, 
irritation, and foreign body sensation in their eyes2.  
Among daily activities, prolonged reading, watching 
televisions and computer visual tasks have shown to 
exacerbate the symptoms of DES3,4. In additions, some 
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climate and environmental conditions have been 
reported to influence DES5-9. For example, low 
humidity (Relative Humidity below 30%) in indoor 
environments such as offices, cars, airplane cabins, 
and extreme temperatures, sun exposure, dust, air 
pollution, and wind in outdoor environments 
exacerbate the symptoms of DES5-9. These 
symptoms, whether mild or severe, transient or 
persistence have been reported to reduce the patients’ 
quality of life10,11.  
The epidemiological studies have reported the 
prevalence rate of DES as 14.6% to 57.5%12-22.       
Due to the widespread use of computers 
professionally or for entertainment, DES is highly 
prevalent in youth23. Artificial tears are among the 
first line of therapy in management of DES24. They 
are used commonly combined with other treatments 
such oral omega-3 essential fatty acid supplements, 
mucin secretagogues, short term steroids and daily 
cyclosporine A, to combat the inflammatory nature 
of the disease25. Frequent eye care visits and different 
treatment options impose high costs to patients and 
health care systems26. 
Due to their non-invasive nature and low side effect 
profile, artificial tears have remained the main stay of 
therapy for DES27. Almost all tear substitutes rapidly 
replace the moisture layer of tears28 and quickly 
reduce the symptoms. In USA, approximately7 to 10 
million Americans spend 320 million dollars per year 
on artificial tear products29. In USA, many clinical 
trials have been conducted to evaluate their efficacy 
and to compare them with each other27.  
In Iran, different brands of artificial tears are 
available in the market. Selecting the proper product 
that suits the patient, with reduced costs remains a 
challenge for the clinician and the patients.  
The purpose of this study was to compare two 
marketed hydroxypropyl methylcellulose (HPMC) 
based artificial tear drops on the improvement of 
DES in young patients after two weeks. An Iranian 
drop [hydroxypropyl methylcellulose 0.3g and 0.1 g 
of Dextran 70, with benzalkonium chloride (BAK) as 
preservative] is manufactured in multi-dose bottles. 
Due to local production, the price and availability of 
this product is adequate. In comparison, a French 
non-persevered hydroxypropyl methylcellulose, 
manufactured in single dose units are imported with 
high costs and the availability might become limited. 
Methods 
This study is double-blind randomized clinical trial. 
The subjects for this study were recruited from the 
students in Shahid Beheshti University of medical 
sciences, Faculty of Rehabilitation Sciences. At first, 
the subjects completed the ocular surface disease 
index (OSDI) questionnaire. The examination of the 
ocular surface and the eyelids was performed with a 
slit lamp biomicroscope to rule out any other ocular 
diseases.  The inclusion criteria were: having a score > 
20 in OSDI questionnaire and no use any types of 
artificial tears during the previous three months. The 
exclusion criteria were as follows: 1- patients with an 
allergy, infection, or eye surface problems (e.g., 
pterygium); 2- patients using contact lenses; 3- 
patients using ophthalmic drugs, such as steroidal or 
non-steroidal anti-inflammatory, antihistamines, and 
glaucoma medications during the previous month, or 
systemically using drugs influencing tear production, 
such as antihistamines, cortisones, hormones, beta-
blockers, antidepressants, and chemotherapy drugs; 4- 
patients with a history of ophthalmic surgical 
operations; 5- patients undergoing radiotherapy; 6- 
patients allergic to hydroxypropyl methylcellulose; 
and 7- pregnant or breastfeeding patients.  
For the patients who met the above criteria, the 
purpose of the study was explained. If willing, they 
were asked to sign the informed consent form which 
was prepared based on the Declaration of Helsinki. 
The protocol was accepted by the Deputy of Research, 
and ethical committee at Shahid Beheshti University 
of medical Sciences. The protocol number is 1392-1-
93-11907. 
Examinations  
The patients were examined in two visits; one before 
the intervention and one after 14±2 days of using the 
specified artificial tear. The following tests were 
performed by the same examiner in two visits and the 
examiner was blind to type of artificial tears used by 
the subjects. 
To assess patients’ DES-related symptoms, a validated 
OSDI questionnaire30 was used. One examiner asked 
the questions from Persian translated version, from 
each participant orally, and filled the corresponding 
responses in the forms. The OSDI, is a 12-question 
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survey, with a five point scale answers (0=none of 
time and 4=all of the time), with higher scores 
representing greater disability. The total OSDI score 
is calculated based on the following formula=100 
(sum of severity for all questions answered)/4 (Total 
number of questions answered), where the severity 
was graded on a scale of: 0=none of the time, 
1=some of the time, 2=half of the time, 3=most of 
the time, 4=all of the time. A score of 100 
corresponds to complete disability while a score 0 
corresponds to no disability. 
Following the completion of the questionnaire, the 
tear break up time (TBUT) assessment was 
performed using  Lowther’s technique in right eye31. 
A sterile fluorescein strip (Indicator, Elham Teb co) 
was moistened using non preserved saline. Excessive 
solution was shaken off. The strip was touched 
gently to the superior bulbar conjunctiva with care, 
not to instill too much solution or cause excessive 
reflex tearing. After a few blinks, the patient was 
asked to close the eyes and then keep them open. The 
time between the eye opening and the appearance of 
the first dry spot was measured in seconds. The 
measurements were taken three times. For each 
subject, the TBUT were averaged and the average 
values were compared before and after the 
intervention. 
The conjunctiva and the cornea were examined after 
instillation of fluorescein, with cobalt blue filter of 
Topcon SL-30 biomicroscope (Tokyo Kogaku Kikai 
K.K, Made in Japan). Punctuate staining was 
recorded using a standardized grading system of 0-3 
for each of the five area on the corneal diagram32.   
The Schirmer test was performed in right eye, with 
anesthetic, measuring the basic tear secretion; a drop 
of Tetracaine 0.5% (Anestocaine, Sina Darou) was 
applied to the eye. The eye was gently dried with 
tissue paper over closed lids to mop up any excess 
secretion. After one minute, the filter paper was 
folded at 5 mm from one end and inserted at the 
junction of the middle and outer third of the lower 
lid. After 5 minutes, the filter paper was removed and 
the amount of wetting was measured by a ruler33.  
Intervention 
The two types of artificial tears contained 
compounds derived from cellulose. The first one was 
a single-dose eye drop, has been made by a French 
company and containing 1.6 mg of hypromellose 
(hydroxypropyl methylcellulose) per 0.5 ml, 
Excipients: (Sorbitol, sodium dihydrogen phosphate 
dehydrate, disodium dodecarbohydrate, water for 
injection) q.s 0.5 ml. The second one was a multi-dose 
eye drop, has been made by an Iranian company, 
containing 0.3 gram hydroxypropyl methylcellulose 
and 0.1 mg of Dextran 70 with the preservative 
benzalkonium chloride (BAK). 
The subjects meeting the inclusion criteria were 
divided into two groups based on their score in OSDI. 
Using random blocks, the first and the second group 
received French and Iranian eye drops, respectively. 
The patients were blind to the names of the medication 
and were instructed to use the eye drops 4 times a day 
for 14 days. In addition, lid hygiene was recommended 
in the mornings; the base of lashes had to be cleaned at 
the lid margins with the foam created by baby 
shampoo (Firouz baby shampoo, Firouz Health 
Group). The patients were asked return to the clinic for 
a follow-up visit in two weeks.  
The independent t test and Chi-square test were used 
to ensure the equality of the two groups at the 
baseline. The results of the two groups, before and 
after intervention, were compared using repeated 
measured ANOVA, with one between subject factor 
and one within subject factor (time: before, after). In 
all analyses, α error was considered to be 0.05. 
Results 
In this study, from 65 patients who participated, only 
58 completed the trial (5 patients in the first group and 
2 patients in the second group did not complete their 
examination). In the first group, one patient showed an 
allergic reaction to the drug, and the drug was 
discontinued immediately. Six patients did not return 
to the clinic for follow-up visit. Therefore, 58 patients 
(27 patients in the first group and 31 patients in the 
second group) were completed the study. The 
difference between the two groups in terms of sex 
distribution was not significant (P=0.149). The mean 
age  of the participants in the first and the second 
group was 24.22±6.43years and 25.97±8.56 years, 
respectively and , there was no significant difference 
between the groups (P=0.393).  
The means and standard deviations of OSDI score, 
TBUT, conjunctival and corneal staining scores, 
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Schirmer test score in the first and the second groups, 
before and after the intervention are presented in 
table 1. 
The OSDI scores after the interventions showed a 
significant decrease to those before the intervention 
(P<0.001). However, the two drugs did not 
significantly differ (P=0.454), and the interaction 
between the drug type and time was not significant 
(P=0.482).The TBUT results after the intervention 
showed a significant increase to those before the 
intervention (P=0.041). However, the two drugs did 
not differ significantly (P=0.514). The interaction 
between drug type and time was not significant 
(P=0.848). 
The conjunctival staining scores after the 
intervention showed a significant decrease to those 
before the intervention (P<0.001). The two drugs 
showed similar effects (P=0.836). Furthermore, the 
interaction between the drug type and time was not 
significant (P=0.094). The corneal staining scores 
after the intervention also showed a significant 
decrease to those before the intervention (P<0.001). 
However, the drugs did not show different effects 
(P=0.807), and the interaction between the type of 
drug and time was not significant (P=0.904). 
The Schirmer test scores, after the intervention 
showed an increase to those before the intervention, 
but the increase was not significant (P=0.143). The 
two drugs showed similar effects (P=0.455), and the 




In this study, hydroxypropyl methylcellulose as the 
effective substance in Iranian and french eye drops 
reduced the symptoms DES equally. The mean score 
of the OSDI questionnaire, in both groups significantly 
decreased after the intervention. When Toda et al.34 
studied the effect of 0.5% HPMC without any 
preservative on Sjögren and non-Sjögren dry eye 
patients they observed that the symptoms were 
reduced in both groups. Nguyen et al35. examined the 
effect of inserts containing HPMC (Lacrisert) on 
patients with DES and found that inserts were 
significantly effective in DES treatment. Lanz36 also 
compared preserved HPMC (GenTeal, 0.3% HPMC, 
with sodium perborate as preservative) vs 
nonpreserved HPMC (Tears Naturale, 0.3% HPMC, 
0.1% dextran 70) and found no significant difference 
between the symptoms of two groups. These findings 
agree with the result of this study. 
In this study, TBUT increased in both groups, but the 
groups did not differ significantly. The reason for this 
improvement could be due to reflex blinking upon 
drop insertion.  More blinking could have helped in 
opening of the meibomian glands, leading to secretion 
of more lipids in tear, and less rate of tear evaporation. 
McCann et al.37 compared the effect of HPMC, 
sodium hyaluronate, and an emulsion (Emustil 
unidose: SIFI) on management of patients with DES 
caused by impaired lipid bilayer. They found that the 
symptoms and tear evaporation were reduced in the 
three groups. Lanz36 found better improvement in 
TBUT with the preserved Genteal. In this study, a 
slightly better improvement was observed with the 
Table 1: Clinical characteristics of the two groups before and after the intervention. 
 




After the intervention 










     Group 2 
(Iranian drop) 
OSDI score 43.72±17.10 39.65±15.91 0.353 32.06±15.35 30.11±16.32 
TBUT (sec) 7±2.5 7.29±2.39 0.654 7.78±2.74        8.23±2.88 
Conjunctival score 6.81±3.02 7.48±2.34 0.348 5.67±2.41        5.23±1.82 
Corneal score 1.37±1.47 1.29±1.21 0.821 0.63±0.92        0.58±0.71 
Schirmer test (mm) 11.18±5.39 11.8±6.26 0.690 11.7±5.60 13.24±6.54 
OSDI: Ocular Surface Disease Index questionnaire                                                                                           
 TBUT: Tear Breakup Time                                                                                                                   
 P value: Level of significance (<0.05) 
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preserved drop but the difference was not significant. 
This difference could be due different preservatives 
used (sodium perborate vs BAK) in two studies. 
The results of Schirmer test (with anesthetic) before 
the intervention did not differ significantly from 
those after the intervention. Although an increase in 
the volume of baseline tear was expected after the 
use of artificial tears, no change was observed. The 
increase in volume might have happened shortly after 
the application of the eye drops and at the time of 
testing, a long time might have passed since the 
instillation of the drop. Lanz36 also found better 
improvement in the Schirmer test with the preserved 
Genteal. In this study, a slightly better improvement 
in observed with the preserved drop but the 
difference was not significant. In this study, a slightly 
better improvement was observed with the preserved 
drop but the difference was not significant. This 
difference could be due different preservatives used 
(sodium perborate vs BAK) in two studies. 
In both groups, the conjunctival and corneal staining 
scores, after the intervention, were reduced 
significantly (P<0.001). The improvement of 
epithelial cells in the cornea and conjunctiva were in 
line with reduction of patients’ complaints. The 
absence of preservative does not appear to be 
advantageous in terms of reducing the corneal and 
conjuntival stains. However, these results might be 
due to the short-term use of these eye drops. Some 
studies have emphasized the side effects of 
preservatives on eye surface and tears, including 
corneal and conjunctival tissue damage, loss of 
goblet cells, preventing the growth of new cells, and 
accelerating cell death38-44. Benzalkonium chloride 
(BAK) is one the most commonly used preservatives 
with good antimicrobial activity27. An exaggerated 
instillation regimen, two drops of 0.02% BAK 
solution, every 3 minutes for 1 hour (i.e. a total of 40 
drops), has shown 4 fold increase in corneal damage; 
while the mild regimen, two drops every 30 minutes 
for 2h, eight drops in total, induces only a minimal 
morphological change45. However other 
preservatives have shown better safety profile than 
BAK27. The incidence of most of the side effects 
depends on concentration of preservatives and long 
duration of their use. Therefore, artificial tears 
without preservatives are still recommended for 
patients with persistent symptoms or those who 
require higher doses of the drops. Although other 
preservatives have shown better safety profile than 
BAK27, but we did not observe any side effects for 
short time about the drop containing BAK. 
Conclusion 
The two artificial tears compared in this study, equally 
reduced the signs and symptoms of DES in two weeks. 
Considering the lower cost and better availability of 
the local product, the Iranian eye drop could be 
prescribed to young patients with transient symptoms 
of DES to impose less cost to these patients. For 
further improvement of signs and symptoms of DES, 
longer clinical trials are required to observe the 
efficacy of these two drops in longer periods and in 
combination with other treatment modalities. 
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